Efficacy of dupilumab and risk factors for dupilumab-induced hypereosinophilia in severe asthma: a preliminary study from China

Efficacy of dupilumab and risk factors for dupilumab-induced hypereosinophilia in severe asthma: a preliminary study from China

AbstractObjective Dupilumab has been approved for the treatment of severe asthma with type 2 inflammation by inhibiting interleukin (IL)-4 and IL-13 signaling. However, dupilumab-induced hypereosinophilia (HE) has been reported and should not be ignored. The aim of this study was to investigate the...

Full description

Bibliographic Details
Main Authors: You Li, Zhenan Deng, Junjie Wen, Changxing Ou, Xiaomin Cen, Yongkang Liao, Qingling Zhang, Jiaxing Xie
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:Annals of Medicine
Subjects:
Dupilumab
severe asthma
efficacy
eosinophils
hypereosinophilia
Online Access:https://www.tandfonline.com/doi/10.1080/07853890.2024.2311843

Similar Items

Similar Items